Lydia specialises in all types of transactions involving intellectual property, including licensing, collaboration agreements, joint ventures, consortium agreements, commercialisation agreements, monetisations and intellectual property aspects of corporate transactions and financings.
Lydia also advises on regulatory compliance issues including product classification, interactions with healthcare professionals, clinical trials, market access, supply chain requirements, marketing and pharmacovigilance.
Lydia has experience in a wide range of industry sectors including life sciences, TMT, energy and infrastructure and finance, but has a particular focus on life sciences and digital health.
- Recent Work
- advising on the £40m Apollo Therapeutics joint venture fund, a collaboration between GlaxoSmithKline, Johnson & Johnson Innovation and AstraZeneca with the technology transfer offices of Imperial College London, University College London and the University of Cambridge
- advising the MHRA’s Clinical Practice Research Datalink in connection with clinical data collection and licensing
- advising Concordia Healthcare on its agreement with Cinven to acquire Amdipharm Mercury Limited for approximately US$3.5bn. The firm advised on IP, pharmaceutical regulatory, pensions and employment law aspects in the UK and the Netherlands
- advising GlaxoSmithKline in connection with the first “open science” collaboration between industry and the Francis Crick Institute
- advising Eisai Co., Ltd on an agreement to license its in-house discovered selective phosphodiesterase 4 (PDE4) inhibitor E6005 to Roivant Sciences Ltd
- advising an international financial institution in connection with its proposed investment in a digital health and wellness business
- advising Peel Hunt LLP (in its capacity as bookrunner and Nominated Adviser to Sensyne Health plc) on the IP, GDPR and life sciences regulatory issues connected with digital health company Sensyne Health plc’s initial public offering on AIM
- advising a multi-national pharmaceutical company on the regulatory classification of a proposed digital health app to complement its existing medicinal products
- advising various pharmaceutical companies and medical device companies on regulatory compliance under EU and national laws, regulations and industry codes, including on global compliance guidelines, interactions with healthcare professionals, multi-centre clinical trials, product promotion and risk mitigation.
Lydia studied Law and French Law at University College London and Université Aix-Marseille II. Lydia teaches on the Oxford University Postgraduate Diploma in IP Law and Practice, is a contributing author to Globe Law and Business’ text “IP Issues in Corporate Transactions: A Practical Guide to the Treatment of Intellectual Property in Acquisitions and Investments” and speaks regularly on licensing and digital health issues.
Lydia has been named as a “rising star” by Managing Intellectual Property IP Stars, and a “Next Generation Lawyer” by Legal 500 and is singled out for her "deep technical understanding". She is also a member of the ABHI’s Legal Issues and Compliance Committee.